How Can We Help?
You are here:
< Back

Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.[1]

It is in development by Merrimack Pharmaceuticals and was awarded orphan drug status for pancreatic cancer.[2]

References

  1. ^ Alternative Names: MM-141. "Istiratumab - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.{{cite web}}: CS1 maint: numeric names: authors list (link)
  2. ^ "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL : USAN (CD-106) ISTIRATUMAB" (PDF). Searchusan.ama-assn.org. Retrieved 2017-05-23.
Categories
Table of Contents